KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash & Current Investments: 2018-2024

Historic Cash & Current Investments for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $293.1 million.

  • Castle Biosciences' Cash & Current Investments rose 2.78% to $287.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 10.76%. This contributed to the annual value of $293.1 million for FY2024, which is 20.58% up from last year.
  • Latest data reveals that Castle Biosciences reported Cash & Current Investments of $293.1 million as of FY2024, which was up 20.58% from $243.1 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' Cash & Current Investments ranged from a high of $409.9 million in FY2020 and a low of $243.1 million during FY2023.
  • Moreover, its 3-year median value for Cash & Current Investments was $258.6 million (2022), whereas its average is $265.0 million.
  • As far as peak fluctuations go, Castle Biosciences' Cash & Current Investments spiked by 314.64% in 2020, and later decreased by 21.54% in 2022.
  • Over the past 5 years, Castle Biosciences' Cash & Current Investments (Yearly) stood at $409.9 million in 2020, then fell by 19.57% to $329.6 million in 2021, then dropped by 21.54% to $258.6 million in 2022, then declined by 6.00% to $243.1 million in 2023, then increased by 20.58% to $293.1 million in 2024.